DIVISLAB

📈 Recent Financial Performance

⭐ Divi’s Laboratories – Latest News & Updates 📈 Recent Financial Performance In the latest reported quarter (Q2 FY26), Divi’s Labs posted strong growth: Net profit jumped by roughly 35% year-on-year. Revenue grew by around 16%, driven by strong API and custom-synthesis demand. Operating margins improved compared to last year as raw-material costs normalized and high-value projects picked up. 🧪 Business Highlights Divi’s remains one of the largest global manufacturers of APIs and intermediates. Strong presence in custom synthesis — supplying to top global pharmaceutical companies. Export-driven business, with customers across more than 100 countries. Continued strong demand in: Nutraceuticals Contrast media Specialty APIs 🏭 Expansion & Capacity Updates A major new unit at Kakinada recently became operational, boosting capacity for both generics and custom synthesis projects. Plants in Hyderabad and Visakhapatnam continue to be expanded to support future product launches. The company has announced multiple growth-capex programs aimed at scaling high-value APIs and increasing backward integration.